Notably, CNVs deletions involving BRCA1 exon 22 and BRCA2 exon 27 have been shown to impair homologous recombination repair, playing a significant pathogenic role in advanced prostate cancer [3,4]. This evidence concerns the gene BRCA1 and prostate carcinoma.